Selective in vitro growth of T lymphocytes from normal human bone marrows
- PMID: 181845
- DOI: 10.1126/science.181845
Selective in vitro growth of T lymphocytes from normal human bone marrows
Abstract
Selective growth of T lymphocytes occurred when unfractionated normal human bone marrow cells were cultured with conditioned medium obtained from phytohemagglutinin-stimulated normal human lymphocytes (Ly-CM). Cultures of up to 90 percent T cells have been maintained for more than 9 months. The T cells exhibited a strict growth dependence upon Ly-CM and were consistently negative for Epstein-Barr viral information.
Similar articles
-
IL-1 inhibits B cell differentiation in long term bone marrow cultures.J Immunol. 1988 Jul 15;141(2):531-8. J Immunol. 1988. PMID: 3260256
-
Thymus-dependent lymphocytes in human bone marrow.J Clin Invest. 1975 Dec;56(6):1491-8. doi: 10.1172/JCI108230. J Clin Invest. 1975. PMID: 1081550 Free PMC article.
-
Human bone marrow lymphocytes. I. Distribution of lymphocyte subpopulations in the bone marrow of normal individuals.J Clin Invest. 1975 Jul;56(1):98-110. doi: 10.1172/JCI108085. J Clin Invest. 1975. PMID: 1079808 Free PMC article.
-
Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion.J Hematother Stem Cell Res. 2002 Aug;11(4):669-74. doi: 10.1089/15258160260194811. J Hematother Stem Cell Res. 2002. PMID: 12201955
-
Factors influencning mitotic yields from suspension cultures of normal and acute leukaemic bone marrows.J Clin Pathol. 1976 Jul;29(7):583-6. doi: 10.1136/jcp.29.7.583. J Clin Pathol. 1976. PMID: 1086308 Free PMC article.
Cited by
-
Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.Bioact Mater. 2024 Sep 10;42:379-403. doi: 10.1016/j.bioactmat.2024.08.046. eCollection 2024 Dec. Bioact Mater. 2024. PMID: 39308543 Free PMC article. Review.
-
A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.Oncoimmunology. 2020 Jun 2;9(1):1770565. doi: 10.1080/2162402X.2020.1770565. Oncoimmunology. 2020. PMID: 32923126 Free PMC article.
-
Toward a molecular understanding of adaptive immunity: a chronology, part I.Front Immunol. 2012 Dec 6;3:369. doi: 10.3389/fimmu.2012.00369. eCollection 2012. Front Immunol. 2012. PMID: 23230443 Free PMC article.
-
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.Front Immunol. 2016 Sep 14;7:353. doi: 10.3389/fimmu.2016.00353. eCollection 2016. Front Immunol. 2016. PMID: 27683579 Free PMC article. Review.
-
Insufficient (sub-native) helix content in soluble/solid aggregates of recombinant and engineered forms of IL-2 throws light on how aggregated IL-2 is biologically active.Protein J. 2012 Oct;31(7):529-43. doi: 10.1007/s10930-012-9429-2. Protein J. 2012. PMID: 22791129
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical